A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

Nandita Vijayasimha, Bengaluru Thursday, February 6, 2025, 08:00 Hrs [IST] ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

The announcement was welcome news for those with major depressive disorder, which affects an estimated 8.3% of the adult population.

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...

The U.S. Food and Drug Administration ( FDA) has approved the use of a nasal spray as a standalone treatment for major depressive disorder, offering a new option for those struggling with ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those who had an inadequate response to oral antidepressants.

The NDA is supported by data from a clinical trial that compared the absorption and efficacy of the nasal treatment with oral and IV bumetanide in 68 healthy adults.

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...

FDA approves esketamine nasal spray as a standalone treatment for adults with treatment-resistant depression, offering rapid ...